TY - JOUR

T1 - Anxiolytic drug discovery

T2 - What are the novel approaches and how can we improve them

AU - Stewart, Adam Michael

AU - Kalueff, Allan V.

PY - 2014/1

Y1 - 2014/1

N2 - Introduction: Contemporary biological psychiatry uses experimental (animal) models to increase our understanding of affective disorder pathogenesis. Despite the well-recognized spectrum nature of affective disorders, modern anxiolytic drug discovery mainly targets specific pathways and molecular determinants within a single phenotypic domain. However, greater understanding of the integrative mechanisms and pathogenesis is essential in order to develop new effective therapies. Areas covered: In this review, the authors emphasize the importance of a 'domain interplay-oriented' approach to experimental affective research. They also highlight the need to expand the scope of anxiolytic drug targets to better understand the pathogenesis of anxiety-spectrum disorders. Expert opinion: There is the potential to markedly improve the utility of animal models for affective disorders. First, the authors suggest that one such way would be by analyzing the systems of several domains and their interplay to better understand disease pathogenesis. Further, it could also be improved by expanding the range of model species and by extending the spectrum of anxiolytic drug targets; this would help to focus on emerging and unconventional systems to better develop new therapies.

AB - Introduction: Contemporary biological psychiatry uses experimental (animal) models to increase our understanding of affective disorder pathogenesis. Despite the well-recognized spectrum nature of affective disorders, modern anxiolytic drug discovery mainly targets specific pathways and molecular determinants within a single phenotypic domain. However, greater understanding of the integrative mechanisms and pathogenesis is essential in order to develop new effective therapies. Areas covered: In this review, the authors emphasize the importance of a 'domain interplay-oriented' approach to experimental affective research. They also highlight the need to expand the scope of anxiolytic drug targets to better understand the pathogenesis of anxiety-spectrum disorders. Expert opinion: There is the potential to markedly improve the utility of animal models for affective disorders. First, the authors suggest that one such way would be by analyzing the systems of several domains and their interplay to better understand disease pathogenesis. Further, it could also be improved by expanding the range of model species and by extending the spectrum of anxiolytic drug targets; this would help to focus on emerging and unconventional systems to better develop new therapies.

KW - Animal models

KW - Anxiety

KW - Deep brain stimulation

KW - Hallucinogenics

KW - Metabolic disorders

KW - Neurobehavioral domains

KW - Obesity

KW - Oxytocin

KW - Vagal nerve stimulation

UR - http://www.scopus.com/inward/record.url?scp=84890497787&partnerID=8YFLogxK

U2 - 10.1517/17460441.2014.857309

DO - 10.1517/17460441.2014.857309

M3 - Review article

C2 - 24206163

AN - SCOPUS:84890497787

VL - 9

SP - 15

EP - 26

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 1

ER -